Lilly Reports Strong First-Quarter 20...(cts will receive the necessary clinical ...),Health

Date:4/20/2009

cts will receive the necessary clinical and manufacturing regulatory approvals or that they will prove to be commercially successful. The company's results may also be affected by such factors as competitive developments affecting current products; rate of sales growth of recently launched products; the timing of anticipated regulatory approvals and launches of new products; regulatory actions regarding currently marketed products; other regulatory developments and government investigations; patent disputes and other litigation involving current and future products; the impact of governmental actions regarding pricing, importation, and reimbursement for pharmaceuticals; changes in tax law; asset impairments and restructuring charges; acquisitions and business development transactions; and the impact of exchange rates and global macroeconomic conditions. For additional information about the factors that affect the company's business, please see the company's latest Form 10-K filed February 2009. The company undertakes no duty to update forward-looking statements.

Alimta(R) (pemetrexed, Lilly)

Byetta(R) (exenatide injection, Amylin Pharmaceuticals)

Cialis(R) (tadalafil, Lilly)

Cymbalta(R) (duloxetine hydrochloride, Lilly)

Efient(R) (prasugrel, Lilly)

Erbitux(R) (cetuximab, ImClone Systems, Lilly)

Evista(R) (raloxifene hydrochloride, Lilly)

Forteo(R) (teriparatide of recombinant DNA origin injection, Lilly)

Gemzar(R) (gemcitabine hydrochloride, Lilly)

Humalog(R) (insulin lispro injection of recombinant DNA origin, Lilly)

Humulin(R) (human insulin of recombinant DNA origin, Lilly)

Posilac(R) (recombinant bovine somatotropin, Lilly)

Strattera(R) (atomoxetine hydrochloride, Lilly)

Symbyax(R) (olanzapine fluoxetine combination, or OFC, Lilly)

Xigris(R) (drotrecogin alfa (activated), Lilly)

Zypadhera(TM) (Lilly)

Zyprexa(R)
'/>"/>

SOURCE Eli Lilly and Company Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
Related medicine news :

1. Statement of Eli Lilly and Company on Dr. David Egilman Settlement:
2. Robert J. Heine, M.D., Ph.D., F.R.C.P. to Join Lilly; Distinguished Diabetes Expert to Lead Diabetes/Endocrine Medical Division
3. Lauren Marangell, M.D. to Join Lilly; Internationally Recognized Expert in Depression Joins as Distinguished Lilly Scholar
4. Genentech/Roches Lucentis and Eli Lillys Ruboxistaurin Will Drive the Diabetic Retinopathy and Nephropathy Drug Markets
5. Lillys CEO Calls for Reform of Nations Drug Safety System
6. Lilly Announces Updates to the Zyprexa and Symbyax U.S. Labels
7. Lilly Grant to VA Will Enhance Services for Returning Combat Veterans
8. Lilly Delivers Strong Third-Quarter Results
9. Lilly and MacroGenics Announce Licensing and Collaboration Agreement
10. Eli Lilly and Company Aids California Recovery Effort
11. Eli Lilly and Company Announces 2007 Lilly Reintegration Awards Recipients